OHSU

Daniel N. Streblow

Streblow

The focus of my laboratory is on defining the role of human cytomegalovirus (HCMV) in the development of vascular disease and chronic rejection of organ allografts. The role of CMV in these diseases is still uncharacterized. My lab will study the following topics: 1) Determining the mechanisms of HCMV-accelerated vascular disease through identification of the viral genes expressed during these diseases using a HCMV microarray chip. Once the viral genes are identified the function of these viral genes will be examined using in vitro and in vivo models of CMV-accelerated vascular disease. 2) Determining the mechanisms of CMV-accelerated vascular disease in rat organ transplantation and rat arotid injury models using cellular- and virus-specific DNA microarrays. The Streblow lab, in conjunction with Dr. Susan Orloff's laboratory at OHSU, has determined both cellular and RCMV in vivo gene expression in infected rats and has begun functional studies of these genes. 3) Determining the immunological mechanisms of viral acceleration of chronic allograft rejection from latently infected donors, which is the most common cause of HCMV-associated disease in transplant patients. 4) Determining the function of CMV-encoded chemokine receptors in the context of viral pathogenesis and acceleration of vascular disease. Dr. Streblow was recently awarded an ONPRC pilot project grant to study Chikungunya in an NHP model.

Biography

Dr. Daniel Streblow received his B.S. in Pharmacology/Toxicology from the University of Wisconsin-Madison in 1992. He graduated from University of Wisconsin-Madison with a Ph.D. in Viral Pathogenesis in 1997. Dr. Streblow received a NIH post-doctoral fellowship and worked with Dr. Jay A. Nelson in the Department of Molecular Microbiology and Immunology at Oregon Health & Science University. He is currently an Assistant Scientist at the Vaccine and Gene Therapy Institute and Department of Molecular Microbiology and Immunology.

Publications

D.N.Streblow, Soderberg-Naucler, C., Vieira, J., Smith, P., Ruchti, F., Mattison, K., and J.A. Nelson. 1999. Vascular smooth muscle cell migration is induced by the Human Cytomegalovirus chemokine receptor US28. Cell. 99:511-21.

D.N. Streblow, van Cleef, K.W., Kreklywich, C.N., Meyer, C., Smith, P, Defilippis, V., Grey, F., Fruh, K., Searles, R., Bruggeman, C., Vink, C., Nelson, J.A., Orloff, S.L. 2007. Rat cytomegalovirus gene expression in cardiac allograft recipients is tissue specific and does not parallel the profiles detected in vitro. J. Virol. 81(8):3816-26.

D.N. Streblow, C.N. Kreklywich, T. Andoh, A.V. Moses, J. Dumortier, P.P. Smith, V. Defilippis, K. Fruh, J.A. Nelson, and S.L. Orloff. 2008. The Role of Angiogenic and Wound Repair Factors During CMV-Accelerated Transplant Vascular Sclerosis in Rat Cardiac Transplants. American J. Transplantation. Feb:8(2):277-87.

C. C. Baca Jones, C.N. Kreklywich, I. Messaoudi, J. Vomaske, E. McCartney, S.L. Orloff, J.A. Nelson, and D.N. Streblow. 2009. Rat Cytomegalovirus Infection Depletes MHC I and II in Bone Marrow Derived Dendritic Cells. Virology May 25;388(1):78-90. Epub 2009 Apr 5.

J. Vomaske, R.M. Melnychuk, P.P. Smith, J. Powell, L. Hall, V. DeFillipis, K. Früh, M. Smit, D.D. Schlaepfer, J.A. Nelson, and D.N. Streblow. .2009.Differential Ligand Binding to a Human Cytomegalovirus Chemokine Receptor Determines Cell Type-Specific Motility. PLOS Pathogens Feb:5(2) e10000304. Epub 2009 Feb 20.